Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Between 18 and 75 years old, inclusive at the time of signing the informed consent;
- Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening;
- Body Mass Index ≥25 kg/m2;
- Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study;
- Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications;
- Has a current HbA1c level >7%, as determined by both screening assessments;
- Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study;
- Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
Exclusion Criteria
- Are unable to understand, consent to, or comply with the study protocol for any reason;
- Currently taking prandial (mealtime) insulin;
Have self-reported measures, collected during screening interview, that reveal:
- An active eating disorder
- The taking of or planning to take (within the next 6 months):
i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications
c. A change in antidepressant or anti-anxiety medication within the past 3 months;
d. A history of bariatric surgery or planned bariatric surgery during the study;
e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances;
f. The current use of tobacco products or use of tobacco products within the past 6 months;
g. The consumption of alcohol above defined thresholds:
i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week
h. An unstable or life-threatening medical illness;
i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period;
j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study.
- Has a current HbA1c level ≥11%, at the screening assessment;
- Concurrent enrollment in any other clinical trial;
- Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.
Sites / Locations
- Study Site
- Study Site
- Study Site
- Study Site
- Study Site
- Study Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
BT-001 + Standard of Care
Standard of Care
BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician